| Alzheimer Disease |
1 |
1 |
| Thromboembolism |
0 |
0.65 |
| Cerebrovascular Accident |
0 |
0.57 |
| Clinical Research |
0 |
0.47 |
| Healthcare and Medical Technology |
0 |
0.36 |
| Acute Stroke |
0 |
0.31 |
| Anticoagulation Therapy |
0 |
0.31 |
| Biomarker |
0 |
0.31 |
| Geriatrics |
0 |
0.31 |
| Arizona |
0 |
0.24 |
| Cerebrospinal Fluid |
0 |
0.24 |
| Edema |
0 |
0.24 |
| Cognitive Impairment |
0 |
0.22 |
| CT Scan |
0 |
0.19 |
| Blood Vessel |
0 |
0.17 |
| A-Scan Biometry |
0 |
0.16 |
| Adverse Effects |
0 |
0.16 |
| Amyloid Plaque |
0 |
0.16 |
| Blood |
0 |
0.16 |
| Clinical Guidelines |
0 |
0.16 |
| Impairment |
0 |
0.16 |
| Mild Cognitive Impairment |
0 |
0.16 |
| Monoclonal Antibody |
0 |
0.16 |
| Scan |
0 |
0.16 |
| Patient Safety |
0 |
0.15 |
| Biologic Therapy |
0 |
0.12 |
| Care and Maintenance of Vision |
0 |
0.12 |
| Cataract |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.1 |
| Brain |
0 |
0.08 |
| Cognition |
0 |
0.08 |
| Dementia |
0 |
0.08 |
| Diffusion Imaging |
0 |
0.08 |
| Hemorrhage |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Medicare |
0 |
0.08 |
| Plasma |
0 |
0.08 |
| Preventive Screening |
0 |
0.08 |
| Seizure |
0 |
0.08 |
| Thrombectomy |
0 |
0.08 |
| Tissue |
0 |
0.08 |
| Amyloidosis |
0 |
0.06 |